Abstract
The poor solubility and wettability of Candesartan cilexetil (CAN) leads to poor dissolution and hence, low bioavailability after oral administration. The aim of the present study was to improve the solubility and dissolution rate and hence the permeability of CAN by preparing solid dispersions/inclusion complexes. Solid dispersions were prepared using PEG 6000 [hydrophilic polymer] and Gelucire 50/13 [amphiphilic surfactant] by melt agglomeration (MA) and solvent evaporation (SE) methods in different drug-to-carrier ratios, while inclusion complexes were made with hydroxypropyl- β-cyclodextrin (HP-β-CD) [complexing agent] by grinding and spray drying method. Saturation solubility method was used to evaluate the effect of various carriers on aqueous solubility of CAN. Based on the saturation solubility data, two drug-carrier combinations, PEG 6000 (MA 1:5) and HP-β-CD (1:1 M grinding) were selected as optimized formulations. FTIR, DSC, and XRD studies indicated no interaction of the drug with the carriers and provided valuable insight on the possible reasons for enhanced solubility. Dissolution studies showed an increase in drug dissolution of about 22 fold over the pure drug for PEG 6000 (MA 1:5) and 12 fold for HP-β-CD (1:1 M grinding). Ex-vivo permeability studies revealed that the formulation having the greatest dissolution also had the best absorption through the chick ileum. Capsules containing solid dispersion/ complex exhibited better dissolution profile than the marketed product. Thus, the solid dispersion/ inclusion complexation technique can be successfully used for enhancement of solubility and permeability of CAN.
Keywords: Candesartan cilexetil, solid dispersions, PEG-6000, hydroxypropyl-β-cyclodextrin, solubility, permeability, Poloxamers, PEG 6000, self-microemulsifying systems, cosurfactants
Current Drug Delivery
Title: Enhancement of Solubility and Permeability of Candesartan Cilexetil by Using Different Pharmaceutical Interventions
Volume: 8 Issue: 4
Author(s): S. M. Shaikh and A. M. Avachat
Affiliation:
Keywords: Candesartan cilexetil, solid dispersions, PEG-6000, hydroxypropyl-β-cyclodextrin, solubility, permeability, Poloxamers, PEG 6000, self-microemulsifying systems, cosurfactants
Abstract: The poor solubility and wettability of Candesartan cilexetil (CAN) leads to poor dissolution and hence, low bioavailability after oral administration. The aim of the present study was to improve the solubility and dissolution rate and hence the permeability of CAN by preparing solid dispersions/inclusion complexes. Solid dispersions were prepared using PEG 6000 [hydrophilic polymer] and Gelucire 50/13 [amphiphilic surfactant] by melt agglomeration (MA) and solvent evaporation (SE) methods in different drug-to-carrier ratios, while inclusion complexes were made with hydroxypropyl- β-cyclodextrin (HP-β-CD) [complexing agent] by grinding and spray drying method. Saturation solubility method was used to evaluate the effect of various carriers on aqueous solubility of CAN. Based on the saturation solubility data, two drug-carrier combinations, PEG 6000 (MA 1:5) and HP-β-CD (1:1 M grinding) were selected as optimized formulations. FTIR, DSC, and XRD studies indicated no interaction of the drug with the carriers and provided valuable insight on the possible reasons for enhanced solubility. Dissolution studies showed an increase in drug dissolution of about 22 fold over the pure drug for PEG 6000 (MA 1:5) and 12 fold for HP-β-CD (1:1 M grinding). Ex-vivo permeability studies revealed that the formulation having the greatest dissolution also had the best absorption through the chick ileum. Capsules containing solid dispersion/ complex exhibited better dissolution profile than the marketed product. Thus, the solid dispersion/ inclusion complexation technique can be successfully used for enhancement of solubility and permeability of CAN.
Export Options
About this article
Cite this article as:
M. Shaikh S. and M. Avachat A., Enhancement of Solubility and Permeability of Candesartan Cilexetil by Using Different Pharmaceutical Interventions, Current Drug Delivery 2011; 8 (4) . https://dx.doi.org/10.2174/156720111795767997
DOI https://dx.doi.org/10.2174/156720111795767997 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery No Association Between GRM3 and Japanese Methamphetamine- Induced Psychosis
Current Neuropharmacology Antimicrobial Action of Chelating Agents: Repercussions on the Microorganism Development, Virulence and Pathogenesis
Current Medicinal Chemistry Climate Changes and Human Health: A Review of the Effect of Environmental Stressors on Cardiovascular Diseases Across Epidemiology and Biological Mechanisms
Current Pharmaceutical Design The Inflammation Paradigm and Coronary Artery Disease: What Celsus, Virchow and Gene Knock Outs Have Taught Us
Cardiovascular & Hematological Disorders-Drug Targets Vascular Endothelium and Hypovolemic Shock
Current Vascular Pharmacology Adrenomedullin in Hypertension
Current Hypertension Reviews The ATP-Binding Cassette Transporter Subfamily A Member 1 (ABC-A1) and Type 2 Diabetes: An Association Beyond HDL Cholesterol
Current Diabetes Reviews Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Gender Differences in Aminoglycoside Induced Nephrotoxicity: A Prospective, Hospital - Based Study
Current Clinical Pharmacology Novel High Throughput Polymer Biocompatibility Screening Designed for SAR (Structure-Activity Relationship): Application for Evaluating Polymer Coatings for Cardiovascular Drug-Eluting Stents
Combinatorial Chemistry & High Throughput Screening Long Non-Coding RNA GAS5 in Age-Related Diseases
Current Medicinal Chemistry Gene Expression Profiling in Rodent Models for Schizophrenia
Current Neuropharmacology Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Current Status of Renal Arterial Endovascular Interventions
Current Hypertension Reviews Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Cardiac Rehabilitation Outcome Following Percutaneous Coronary Intervention Compared to Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets